Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 17, 2023 Category: Hematology Authors: Jonas S. Heitmann, Richard F. Schlenk, Daniela D örfel, Sabine Kayser, Konstanze Döhner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Märklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Gr Tags: Research Source Type: research
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
(Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 15, 2023 Category: Hematology Authors: Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng and Qiangsong Tong Tags: Retraction Note Source Type: research
Synergistic efficacy of simultaneous anti-TGF- β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not s... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 12, 2023 Category: Hematology Authors: Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu and Kongming Wu Tags: Research Source Type: research
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immuno... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 8, 2023 Category: Hematology Authors: Matthieu Roulleaux-Dugage and Antoine Italiano Tags: Editorial Source Type: research
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 3, 2023 Category: Hematology Authors: Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo and Yongping Song Tags: Correspondence Source Type: research
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly le... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 3, 2023 Category: Hematology Authors: Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D. Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K. Balasubramanian, Hussein Awada, Ramsha Ahmed, Minako Mori, Manja Meggendorfer & helli Tags: Research Source Type: research
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 3, 2023 Category: Hematology Authors: Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo and Yongping Song Tags: Correspondence Source Type: research
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
RNA modification has recently become a significant process of gene regulation, and the methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification, methylating various types of ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - August 2, 2023 Category: Hematology Authors: Ya-Nan Qi, Zhu Liu, Lian-Lian Hong, Pei Li and Zhi-Qiang Ling Tags: Review Source Type: research
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 31, 2023 Category: Hematology Authors: Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Br äunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, E Tags: Research Source Type: research
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions
NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 31, 2023 Category: Hematology Authors: Dong-Jun Fu and Ting Wang Tags: Review Source Type: research
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
Antibody –drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 28, 2023 Category: Hematology Authors: Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li and Xiaonan Chen Tags: Correspondence Source Type: research
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 28, 2023 Category: Hematology Authors: James F. Wu and Binod Dhakal Tags: Correspondence Source Type: research
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the infl... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 27, 2023 Category: Hematology Authors: Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu and Jing Nie Tags: Correspondence Source Type: research
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival vers... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 27, 2023 Category: Hematology Authors: Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu and John Mascarenhas Tags: Review Source Type: research
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recrui... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - July 27, 2023 Category: Hematology Authors: Antonio Tapia-Galisteo, Luis Álvarez-Vallina and Laura Sanz Tags: Review Source Type: research
